atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
atai Life SciencesAccomplished enrollment of Section 2a proof-of-concept, randomized, double-blind, placebo-controlled scientific trial of PCN-101 (R-ketamine).Final affected person anticipated to ...